Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer

Page 1

	Year	Citations
Palbociclib and Letrozole in Advanced Breast Cancer Richard S. Finn, Miguel Martín, Hope S. Rugo, New England Journal of Medicine	2016	2.8K
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Richard S. Finn, John Crown, István Láng, The Lancet Oncology Cyclin-dependent Kinase 4/6Breast OncologyInhibitor PalbociclibMedicinePharmacology	2014	1.9K
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3) Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell, The Oncologist	2016	243
Abstract GS5-06: A U.S. food and drug administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapy Harpreet Singh, LJ Howie, Erik Bloomquist, Cancer Research Breast OncologyCancer ManagementGynecologyPharmacotherapyGynecology Oncology	2018	15

Page 1